Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan

Journal of Medical Economics

Volumn 15, Issue 1, 2012, Pages 175-184

  Henk, Henry J ^a   Kaura, Satyin ^b  

^a OPTUM   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bisphosphonate; Bone metastasis; Breast cancer; Pamidronate; Skeletal related event; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT CARE PLANNING; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DATABASES, FACTUAL; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; HYPERCALCEMIA; IMIDAZOLES; INSURANCE CLAIM REVIEW; MEDICARE PART C; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SPINAL CORD COMPRESSION; UNITED STATES;

EID: 84856028702     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.632044     Document Type: Article

References (37)

1. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9:14-27 (Pubitemid 39363165)
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94 (Pubitemid 27444031)
3. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90 (Pubitemid 30127670)
4. Weinfurt KP, Castel LD, Li Y, et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004;42:164-75
5. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-7 (Pubitemid 47557312)
6. Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006;17:1072-82 (Pubitemid 43985242)
7. Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7 (Pubitemid 44420137)
8. Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 2003;8:469-88 (Pubitemid 37522661)
9. Zometa® (zoledronic acid) Injection package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 2011
10. Aredia® (pamidronate disodium) for injection package insert. East Hanover NJ: Novartis Pharmaceuticals Corporation, 2011
11. Holen I, Coleman RE. Bisphosphonates as treatment of bone metastases. Curr Pharm Des 2010;16:1262-71
12. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44 (Pubitemid 37238631)
13. Rosen LS, Gordon DH, Dugan Jr. W, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100: 36-43 (Pubitemid 37553537)
14. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45
15. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bispho-sphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-32
16. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44 (Pubitemid 28265038)
17. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
18. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28: 5132-9
19. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bispho-sphonates in early breast cancer. Cancer Treat Rev 2008;34:453-75
20. Lipton A. Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 2008;34: S25-S30
21. Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-68 (Pubitemid 30175914)
22. Ottewell PD, Monkkonen H, Jones M, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100:1167-78
23. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, et al. Sequence-and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005;113: 364-71 (Pubitemid 40038702)
24. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421-8
25. Rack B, Jückstock J, Genss E, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010;30:1807-13
26. Lin AY, Park JW, Scott J, et al. Zoledronic acid as adjuvant therapy for women with early-stage breast cancer and disseminated tumor cells in bone marrow. Presented at 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 30 May-3 June 2008. Abstract 559
27. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360: 679-91
28. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Overall survival with adjuvant zoledronic acid in premenopausal breast cancer patients with complete endocrine blockade-long-term results from ABCSG-12. Poster presented at 2011 ASCO Annual Meeting, Chicago, IL, 3-7 June 2011. Abstract 520
29. Eidtmann H, de Boer R, Bundred NJ, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010;21:2188-94
30. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365:1396-1405
31. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102: 1099-105
32. Zaghloul MS, Boutrus R, El-Hosieny H, et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010;15:382-9
33. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-99
34. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009;125:1705-9
35. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010;28:3582-90
36. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010;102:799-802
37. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010;28:3577-81